Literature DB >> 2275892

Mechanism of action of sotalol in supraventricular arrhythmias.

P Brugada1, J L Smeets, J Brugada, J Farré.   

Abstract

Sotalol has a virtually unique antiarrhythmic profile in that it combines the properties of the Class II beta-blocking agents with the Class III properties that prolong repolarization. The Class II action exerts a marked effect on atrioventricular nodal conduction and makes sotalol a suitable drug for the treatment of adrenergic-induced supraventricular tachycardias. Sotalol helps to prevent or slow supraventricular arrhythmias involving the atrioventricular node as part of a reentrant pathway and also helps to control the ventricular rate during supraventricular arrhythmias conducted to the ventricles over the normal atrioventricular pathway. The capacity of conduction of accessory pathways is diminished by sotalol, thereby decreasing the ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. The effects of sotalol on conduction of the cardiac impulse (Class I effects) have been probably overlooked and those on true refractoriness (Class III effects) overestimated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275892     DOI: 10.1007/bf00357040

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  4 in total

1.  Arrhythmogenesis of antiarrhythmic drugs.

Authors:  P Brugada; H J Wellens
Journal:  Am J Cardiol       Date:  1988-05-01       Impact factor: 2.778

Review 2.  Spectrum of supraventricular tachycardias.

Authors:  P Brugada; J L Smeets; H J Wellens
Journal:  Am J Cardiol       Date:  1988-12-20       Impact factor: 2.778

3.  Effects of oral amiodarone on rate-dependent changes in refractoriness in patients with Wolff-Parkinson-White syndrome.

Authors:  P Brugada; H J Wellens
Journal:  Am J Cardiol       Date:  1985-11-15       Impact factor: 2.778

4.  Ventricular arrhythmias: mechanisms and actions of antiarrhythmic drugs.

Authors:  H J Wellens; P Brugada; J Farre
Journal:  Am Heart J       Date:  1984-05       Impact factor: 4.749

  4 in total
  1 in total

Review 1.  Improving Atrial Fibrillation Therapy: Is There a Gene for That?

Authors:  William J Hucker; Alan Hanley; Patrick T Ellinor
Journal:  J Am Coll Cardiol       Date:  2017-04-25       Impact factor: 24.094

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.